{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:28:57Z","timestamp":1790378937026,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.rmed.2009.07.008","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T05:39:40Z","timestamp":1250228380000},"page":"1838-1853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany"],"prefix":"10.1016","volume":"103","author":[{"given":"R.","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schaberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Loddenkemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nienhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2009.07.008_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","article-title":"Predictive value of a whole-blood IFN-\u03b3 assay for the development of active TB disease","volume":"177","author":"Diel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3111\/13696990701605235","article-title":"Economic evaluation in health: saving money or improving care?","volume":"10","author":"Chisholm","year":"2007","journal-title":"J Med Econ"},{"key":"10.1016\/j.rmed.2009.07.008_bib3","first-page":"657","article-title":"Recommendations for\u00a0environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis","volume":"58","author":"Diel","year":"2007","journal-title":"Pneumologie"},{"key":"10.1016\/j.rmed.2009.07.008_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"Claxton","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.rmed.2009.07.008_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0266462301104083","article-title":"Bayesian cost-effectiveness analysis. An example using the GUSTO trial","volume":"17","author":"Fryback","year":"2001","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.rmed.2009.07.008_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archinternmed.2008.524","article-title":"Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers","volume":"169","author":"De Perio","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib7","first-page":"1414","article-title":"Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts","volume":"12","author":"Marra","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/502343","article-title":"Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculisis exposure: a cost-effectiveness analysis","volume":"25","author":"Salpeter","year":"2004","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.rmed.2009.07.008_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/09031936.06.00005906","article-title":"Direct costs of three models for the screening of latent tuberculosis infection","volume":"28","author":"Wrighton-Smith","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.07.008_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/593965","article-title":"Does the implementation of an interferon-g release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?","volume":"30","author":"Sahni","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.rmed.2009.07.008_bib11","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"17","author":"Ferebee","year":"1970","journal-title":"Adv Tuberc Res"},{"key":"10.1016\/j.rmed.2009.07.008_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Making"},{"key":"10.1016\/j.rmed.2009.07.008_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hec.614","article-title":"Stochastic league tables: communicating cost-effectiveness results to decision-makers","volume":"10","author":"Hutubessy","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.rmed.2009.07.008_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib15","first-page":"295","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock","year":"1999","journal-title":"AJRCCM"},{"key":"10.1016\/j.rmed.2009.07.008_bib16","first-page":"355","article-title":"Treatment of tuberculosis and tuberculosis infection in adults and children","volume":"134","author":"American Thoracic Society","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.7326\/0003-4819-71-6-1113","article-title":"Serum transaminase elevations and other hepativ abnormalities in patients receiving isoniazid","volume":"71","author":"Scharer","year":"1969","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin \u2013 a meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2009.07.008_bib19","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"Smieja","year":"1999","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmed.2009.07.008_bib20","first-page":"555","article-title":"International Union Against Tuberculosis committee on prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"Thompson","year":"1982","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.rmed.2009.07.008_bib21","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib22","first-page":"486","article-title":"Isoniazid related fatal hepatitis","volume":"164","author":"Millard","year":"1996","journal-title":"West J Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2009.07.008_bib24","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis","volume":"159","author":"Salpeter","year":"1993","journal-title":"West J Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"Lo Bue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib27","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib28","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.rmed.2009.07.008_bib29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199457110-00029","article-title":"A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients","volume":"57","author":"John","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.rmed.2009.07.008_bib30","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2009.07.008_bib31","unstructured":"Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2006, Berlin; 2008."},{"key":"10.1016\/j.rmed.2009.07.008_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.7326\/0003-4819-127-12-199712150-00001","article-title":"Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk benefit and cost-effectiveness analysis","volume":"127","author":"Salpeter","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2009.07.008_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10198-004-0236-3","article-title":"The cost structure of lung tuberculosis in Germany","volume":"5","author":"Diel","year":"2004","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.rmed.2009.07.008_bib34","author":"Gesundheitsberichterstattung des Bundes"},{"key":"10.1016\/j.rmed.2009.07.008_bib35","author":"Einheitlicher Bewertungsma\u00dfstab"},{"key":"10.1016\/j.rmed.2009.07.008_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2007-963505","article-title":"Deutsche Empfehlungen zur gesundheits\u00f6konomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens","volume":"12","author":"Schulenburg","year":"2007","journal-title":"Gesundh \u00f6kon Qual mang"},{"key":"10.1016\/j.rmed.2009.07.008_bib37","unstructured":"Statistisches Bundesamt. Volkswirtschaftliche Gesamtrechungen; Fachserie 18, Reihe 1.2 2. Vierteljahr 2008, 2.15 Lohnkosten je Arbeitnehmer. Wiesbaden; 2008."},{"key":"10.1016\/j.rmed.2009.07.008_bib38","article-title":"Arbeitsunf\u00e4higkeit bei AOK-Pflichtmit-gliedern ohne Rentner (Arbeitsunf\u00e4higkeitsf\u00e4lle und Arbeitsunf\u00e4higkeitstage, Tage je Fall)","author":"Gesundheitsberichterstattung des Bundes","year":"2007","journal-title":"Jahr"},{"key":"10.1016\/j.rmed.2009.07.008_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1183\/09031936.06.00011806","article-title":"Cost-optimisation of screening for latent tuberculosis in close contacts","volume":"28","author":"Diel","year":"2006","journal-title":"Eur Respir J"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611109002285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611109002285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:50:42Z","timestamp":1760611842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611109002285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0954611109002285"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2009.07.008","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2009.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}